Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Operations: 2019-2024

Historic Cash from Operations for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$347.2 million.

  • Beam Therapeutics' Cash from Operations rose 7.54% to -$81.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$338.2 million, marking a year-over-year decrease of 149.01%. This contributed to the annual value of -$347.2 million for FY2024, which is 132.75% down from last year.
  • Beam Therapeutics' Cash from Operations amounted to -$347.2 million in FY2024, which was down 132.75% from -$149.2 million recorded in FY2023.
  • In the past 5 years, Beam Therapeutics' Cash from Operations ranged from a high of $22.5 million in FY2022 and a low of -$347.2 million during FY2024.
  • For the 3-year period, Beam Therapeutics' Cash from Operations averaged around -$158.0 million, with its median value being -$149.2 million (2023).
  • Per our database at Business Quant, Beam Therapeutics' Cash from Operations skyrocketed by 133.99% in 2022 and then plummeted by 762.29% in 2023.
  • Beam Therapeutics' Cash from Operations (Yearly) stood at -$95.7 million in 2020, then skyrocketed by 30.78% to -$66.3 million in 2021, then spiked by 133.99% to $22.5 million in 2022, then crashed by 762.29% to -$149.2 million in 2023, then crashed by 132.75% to -$347.2 million in 2024.